Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib in Relapsed/Refractory Ovarian Cancer
NCT03166891Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of chiauranib in ovarian cancer, sponsored by Akeso, Inc.. Started Dec 2017; status: completed.
02
Drugs
chiauranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03166891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166891.